

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2019

**FOAMIX PHARMACEUTICALS LTD.**

(Exact name of registrant as specified in its charter)

**Israel**  
(State or other jurisdiction of incorporation)

**001-36621**  
(Commission File Number)

**N/A**  
(IRS Employer Identification No.)

**2 Holzman Street,  
Weizmann Science Park  
Rehovot, Israel**  
(Address of principal executive offices)

**7670402**  
(Zip Code)

**+972-8-9316233**  
(Registrant's telephone number, including area code)  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value NIS 0.16 per share	FOMX	Nasdaq Global Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

On November 7, 2019, Foamix Pharmaceuticals Ltd. issued a press release entitled “Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic.” A copy of the press release is attached as Exhibit 99.1 to this report.

**Item 9.01 Financial Statements and Exhibits.****(d) Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press release entitled “Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic.” dated November 7, 2019.</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2019

**FOAMIX PHARMACEUTICALS LTD.**

By:           /s/ Mutya Harsch            
Mutya Harsch  
Chief Legal Officer

---

---



**Foamix Announces Issuance of New U.S. Patent for Compositions  
Combining a Retinoid and a Tetracycline Antibiotic**

**REHOVOT, Israel, and BRIDGEWATER, NJ, November 7, 2019** – Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders. This newly issued patent, which expires in 2030, is the latest U.S. patent to be issued to Foamix in connection with Foamix’s drug development programs for treating acne vulgaris.

“We are delighted with the addition of this new patent, which provides additional coverage for our combination product candidate, FCD105, a topical foam for moderate-to-severe acne with a retinoid and minocycline,” said David Domzalski, Chief Executive Officer of Foamix. “The patent demonstrates our continued development of our patent portfolio and our commitment to innovation in dermatology.”

**About Foamix Pharmaceuticals**

Foamix is a specialty pharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize solutions that were long thought impossible, including the world’s first topical minocycline, AMZEEQ. Its proprietary Molecule Stabilizing Technology (MST™) is utilized in the Company’s dermatology products and in other products currently in development: FMX103 for the potential treatment of moderate to severe papulopustular rosacea and FCD105 for the potential treatment of moderate to severe acne

Foamix is a different type of specialty pharmaceutical company by design, driven to see the solutions, overcome barriers in all aspects of business, and reimagine what’s possible for conditions with high unmet needs.

Foamix uses its website as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities and Exchange Commission, public conference calls, and webcasts. For more information, visit [www.foamix.com](http://www.foamix.com).

**Corporate Contact:**

Ilan Hadar, CFO  
Foamix Pharmaceuticals Ltd.  
+972-8-9316233  
[ilan.hadar@foamixpharma.com](mailto:ilan.hadar@foamixpharma.com)

**Media Relations:**

Vusi Moyo  
Zeno Group  
312-396-9703  
[vusi.moyo@zenogroup.com](mailto:vusi.moyo@zenogroup.com)

**U.S. Investor Relations:**

Joyce Allaire  
LifeSci Advisors, LLC  
646-889-1200  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)

---